Priced for a smaller company: management is quietly telling investors the business has already outgrown what the numbers
The model's full reasoning — Q2 2022 call → NOThe question asks whether management conveys that outsiders are currently underweighting something the company has already done, and whether management points to at least one concrete, already-completed or already-operating piece of the business whose contribution is still largely ahead of the reported results. Let me analyze the transcript. Key themes from the call: 1. Operational success - stalls placed, throughput up 66% 2. Commercial progress - partnerships with Pilot/GM, Cadillac, Delta Electronics 3. Regulatory work - NEVI program, Inflation Reduction Act 4. Technology innovation - Autocharge+, PlugShare, Innovation Lab Now, does management convey a recognition gap - that outsiders are underweighting something already done? Let me look for this. Cathy Zoi talks about the Pilot/GM partnership as "the first major announcement of the EVgo eXtend offering." Olga discusses the cash flow profile of the eXtend model versus the core model, noting that eXtend "sees positive cash flow immediately" because the customer incurs capital expenditures while EVgo generates margin. Is there a sense that the market is underweighting something? Let me look at the Q&A. In the Q&A, when asked about the eXtend model and how big it can become, Cathy says "we're very well placed to have that be a part of our business going forward." When asked about the NEVI program, Cathy says "we become kind of a thought leader for state DOT's" and "we're really well placed." Hmm, but is there a specific recognition gap that management itself raises? Let me look more carefully. Olga discusses the cash flow profile of eXtend versus core model - this is explaining the model, not necessarily saying the market is underweighting it. Actually, let me reconsider. The question asks about whether management conveys that outsiders are currently underweighting something the company has ALREADY DONE. Looking at the Pilot/GM partnership - this was announced in July (a few weeks before the call). It's already signed/closed. And Olga says the revenues from it "are scheduled to kick in closer to Q4 second half of the year" and that the forecast is "more heavily loaded towards the second half of the year" because of "the kicking of certain contractual revenues by the end of Q3 beginning of Q4, namely from the new PFJ contract." So the Pilot/GM deal is already signed, and its contribution is still ahead.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| OEC | Orion Engineered Carbons S.A. | Q4 2022 | 2023-02-17 | B+ |
| KEY | KeyCorp | Q3 2022 | 2022-10-20 | B+ |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
PRPH · Q1 2023 → YESThe question is: Does management convey that outsiders are currently underweighting something the company has already done, and do they point to at least one concrete, already-completed or already-ope...YES The transcript shows management explicitly framing the current market view as mismatched with the company's actual position: "Anybody that's focused on us for earnings, you invested or are following the wrong company," "we're not an earnings story this year," and "focus less on revenues and earnings. This is a transition year." They repeatedly contrast this with the multi-billion-dollar assets already built and operating, whose contributions are still ramping or largely ahead. Concrete already-real items with meaningful payoff still ahead include: - The manufacturing facility (already at capacity, running nearly 100% YoY growth, with $25M revenue target for 2024 constrained only by capacity expansion this year; estimated $70M valuation next year plus $40M working capital and tens of millions in equipment). - Nebula Genomics (already generating >100% YoY revenue growth via direct-to-consumer sales; in-house whole-genome processing and B2B ramp expected in H2 202 3, particularly Q4, after validations complete in a couple of months).
KEY · Q3 2022 → YESThe question is: Does management convey that OUTSIDERS ARE CURRENTLY UNDERWEIGHTING SOMETHING THE COMPANY HAS ALREADY DONE — and does management answer that gap by pointing to at least one CONCRETE, A...YES Management repeatedly frames its interest-rate-risk positioning as something that “sets Key apart” and creates “unique and significant upside” that is not yet reflected in the market’s view of the company. Chris Gorman states that the $1.2 billion annualized benefit from re-pricing existing short-term Treasuries and swaps “ even in the event that rates remain at current levels” will arrive over the next two years, and Don Kimble confirms the same mechanics and timing. The $9 billion in short-term Treasuries and $26 billion in swaps are already on the balance sheet; the contribution is simply not yet in the reported results.
KIM · Q2 2018 → YESThe question is: Does management convey that outsiders are currently underweighting something the company has already done, and do they point to at least one concrete, already-completed or already-ope...YES Management explicitly frames the public-private pricing disconnect as a gap in how the company is valued versus its actual assets and execution. They point to the already-completed Toys "R" Us liquidation process (22 boxes resolved into OpCo and PropCo leases, with seven OpCo leases already signed and seven PropCo under 18-24 month resolution) as a concrete, already-real item whose rent contribution is still largely ahead in the reported results, with the 70-80 bps impact on occupancy and same-site NOI expected to be recaptured in Q3 and beyond.